Thiethylperazine

CHEMBL1378 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
399.6 g/mol
LogP
5.4
Phase
4

Thiethylperazine is a phenothiazine antipsychotic with potent dopamine D2 receptor antagonist activity, used clinically as an antiemetic for the prevention and treatment of nausea and vomiting, including postoperative nausea and chemotherapy-induced emesis, through blockade of dopamine receptors in the chemoreceptor trigger zone. It also blocks muscarinic, histaminergic, and alpha-adrenergic receptors, contributing to its antiemetic efficacy and adverse effect profile. Its use has declined with the availability of more selective antiemetic agents.

Khối lượng phân tử

399,6000 g/mol

LogP

5,40

TPSA

60,30 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2

InChI

InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3

Molecular Formula

C22H29N3S2

HBD / HBA

- / 5

Liên kết có thể quay

6

Nguyên tử nặng

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Thiethylperazine is a phenothiazine antipsychotic with potent dopamine D2 receptor antagonist activity, used clinically as an antiemetic for the prevention and treatment of nausea and vomiting, including postoperative nausea and chemotherapy-induced emesis, through blockade of dopamine receptors in the chemoreceptor trigger zone. It also blocks muscarinic, histaminergic, and alpha-adrenergic receptors, contributing to its antiemetic efficacy and adverse effect profile. Its use has declined with the availability of more selective antiemetic agents.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Thiethylperazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1378. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5440. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.